pharma holt len
holt insight balanc sheet esg
report look valuat impli return univers use three credit
algorithm holt len linker incorpor forecast pharmavalu npv
essenti dcf model focu differ compani attribut holt default
linker combin forecast cfroi asset growth calcul object dcf
valuat holt linker essenti link full forecast allow
us captur visibl patent expiri beyond default two-year consensu model
margin impact announc deal pharmavalu build product-by-product npv also
discuss esg metric highlight recent inter-compani cross-sector perform
resourc intens account qualiti cash flow deploy
holt eu pharma market-impli discount rate remain high compar
defens sector europ eu pharma look attract rel market
expect consensu forecast believ reflect us polit
uncertainti futur us price
holt default see averag downsid eu major upsid eu
specialti holt linker see upsid eu major upsid eu
specialti pharma find holt approach especi use analys pharma
balanc sheet ifr allow captur invest allow
meaning discuss return metric
pharmavalu npv suggest broadli fair valu eu major still trade larger
discount npv us peer pharmavalu strong long-term record
perform stock bought ev/npv low sold ev/npv high
eu stock consist upsid across metric sanofi almiral
consist downsid across metric orion recordati
credit suiss connect seri leverag
except breadth macro micro research
deliv incis cross-sector cross-bord
themat insight client
figur comparison variou price target compani rank order cs price target current share price
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
differ current price target priceholt defaultholt linkerequ pharmavalu pharmavalu pharmavalu npv charl martineau univers toronto
tabl content
holt linker allow long-term explicit forecast
invest return overst lack captur invest ifr balanc sheet
cfroi novo stand best long-term perform
holt scorecard better growth indic valuat
perform holt invest style global econom cycl
holt account qualiti eu pharma vs sector
eu analyst perspect account
pay perform
 lifeblood industri
 return pharmavalu
summari rate target price
pharma holt len
credit suiss holt discount rate pharma sector impli eu sector
remain expens rel global market holt metric posit
market price lower cfroi cash flow return invest growth holt
expect eu pharma make sector attract defens
sector consum stapl recent posit earn revis suggest
outsid holt see us polit risk enter next elect cycl
believ could translat manag caution earn guidanc suspect
recent posit eu pharma revis reflect fx weak report currenc
dollar earner continu strong em underli growth
holt balanc sheet see holt balanc sheet analysi import adjunct
analysi adjust tradit expens capitalis
see truer refect invest capit base adjust balanc sheet
see cfroi major pharma includ impact goodwil
specialti pharma around current cost capit novo stand
highest sustain cfroi almiral azn see biggest cfroi improv
holt default suggest averag downsid eu major pharma
specialti pharma stock highest upsid holt default roch
specialti highest upsid come lundbeck ucb
holt linker add greater perspect take explicit cs forecast
revert algorithm fade longer explicit growth elimin excess
cash act redress return result higher upsid linker basi holt
typic see upsid major upsid specialti compani
compani highest upsid holt linker lundbeck
almiral ucb
pharmavalu offer dcf approach base product-by-product analysi highest
upsid equiti npv eu major sanofi specialti pharma
almiral azn roch show highest sensit success
holt scorecard add momentum qualiti valuat metric roch
recordati orion score well
account qualiti major theme eu pharma compani includ
dispos gain incom compani routin ignor acquir amortis
analysi eu pharma versu sector show higher degre uplift non-
ep holt rate sanofi bayer among eu major rel weak
account although neither stand us poor cash flow convers
among specialti compani merck kgaa rate weakest holt also
show poor cash convers analysi
esg measur pharma score well rel sector resourc intens
per unit profit best perform biotech winner sell highli price specialti drug
may score well access metric holt also look long-term econom profit
gener ceo pay roch novo appear offer highest econom profit per
us dollar ceo pay
 product see stabl overal product evid scale
advantag accord pharmavalu azn novo highest product
recent spend azn novarti almiral highest replac power
deploy critic factor expect adjust free cash flow
gener eu univers next five year unalloc
model avail acquisit increment return investor
pharma holt len
len linker pharmavalu essenti dcf model differ area
focu model underli cash flow report set valuat
eu univers pharma compani use three differ framework add
contextu data global compani appropri
global pharma valuat holt default
sector continu look expens rel broader market market-
impli discount rate remain global market subsector bar
japan pharma sinc septemb eu univers simpl averag
individu compani holt default suggest averag upsid eu major
pharma upsid eu specialti current level
proprietari holt methodolog aim remov subject compani account
convert incom balanc sheet inform cfroi perform measur creat
object represent compani underli econom holt warrant valuat
base histor perform two year consensu forecast research
thousand compani similar characterist perform histor holt default
output compar across sector region
compani high level goodwil acquisit score well holt default
linker goodwil treat non-oper asset goodwil typic account
holt balanc sheet exclud goodwil invest base typic increas
cfroi sector boost default linker holt warrant price
global pharma discount rate remain histor low use holt default best
way assess attract sector look market-impli discount rate
higher discount rate attract subsector figur show global
pharma holt default market-impli discount rate remain low compar histori
fallen broadli line global market sinc subseg except
japan pharma shown market-impli discount rate aggreg market sinc
septemb believ out-performance sector past year
reflect emerg sustain pipelin new product improv margin
attribut posit mix shift specialti drug us biotech notion attract
subseg today market-impli discount rate eu eu major pharma
similarli valu market-impli discount rate respect
global rate
figur market impli discount rate guid rel attract higher discount rate attract
pharma holt len
holt aggreg eu pharma vs sector
despit low market-impli discount rate european pharma rel global
market look within europ holt see sector one attract
defens sector section look holt market-impli cfroi expect
ep revis metric eu pharma look attract rel defens sector
either med tech consum stapl
figur compar level cfroi price market compar holt default
expect specif rank sector level differ market-
impli cfroi green dot holt forecast cfroi estim pale blue bar lower
market expect rel holt forecast cheaper sector
compar typic defens sector consum stapl healthcar
sector remain attract forecast cfroi market-impli cfroi
figur market expect cfroi vs key sector
histor market expect drift lower consensu
estim sector notabl pick narrow spread two
think investor remain concern particularli potenti disrupt us price reform
nois next elect cycl despit robust earn growth expect sell-sid
driven continu shift biolog higher margin strong em perform
support estim
figur spread market-impli cfroi cfroi
term momentum cfroi revis form measur earn revis rank
among posit sector suggest good time enter
sector
pharma holt len
pharma comm servicesindustrialsfinancialsutilitiesconsumerstaplesr estatem sectorscfroi differ time periodscfroi yr mediancfroi last fiscal yearcfroi forecastmarket impli cfroilow market expect rel forecast cheap higher market expect rel forecast charl martineau univers toronto octob
figur cfroi revis vs sector
pharma holt linker show upsid
holt linker indic averag upsid eu major upsid
holt default valuat pose challeng pharma sector use robust
methodolog alongsid long-term forecast use holt linker allow us
captur impact visibl pivot event patent expiri gener known
least five year advanc captur expect inflect known pipelin
develop bolt-on linker work also standardis discount rate limit
cash accumul latter adjust typic improv appar return lift
warrant price avoid artifici depress return
global pharma line pharmavalu histor averag
eu pharma continu trade around pariti pharmavalu ev/npv
remain cheapest subsector sinc japan pharma maintain
premium ev/npv
pharmavalu product-by-product npv valuat pharma compani use
proprietari life-cycle algorithm valu drug key geographi across global credit
suiss univers see rel valuat tool look across univers global
stock consist basi typic look year asset onward
use methodolog annual pick global long/short portfolio strong record
gener invest perform detail long term perform pleas
see global pharmaceut pharmavalu assess valu
pharma holt len
figur set upside/downsid impli variou valuat approach rank
order potenti upsid target price
stock consist upsid almiral sanofi
almiral top pick kept us infrastructur lost us dermatolog sale
abl profit immedi acquisit allergan dermatolog unit success
initi launch seysara acn support view dermatologist respond well
new innov next leg growth come europ roll-out skilar
ilumetri psoriasi asset tiranibulin actin keratosi
lebrikizumab atop dermat almiral may offer innov skilar oral product
abil offer lower price major compani competitor
sanofi compani trade discount npv time investor remain
concern cash flow would poorli reinvest view support write-off
valu bioverativ less year launch new senior manag opportun
focu compani success core asset take enough cost off-set
dilut impact regeneron jv
stock consist downsid orion recordati
orion orion finland-bas compani domin posit domest gener
price pressur remain eu infrastructur sell rang drug
brand gener respiratori drug biosimilar group success negoti loss
incom follow main patent loss parkinson franchis remain sceptic
prospect nubeqa prostat cancer partner bayer sharehold
taken lion share cash flow dividend leav limit opportun view
recordati consist record organ acquisit growth driven top
bottom line new privat equiti ownership believ investor expect
acquisit growth acceler
figur potenti upside/downsid variou valuation-bas target price
credit suiss holt pharmavalu credit suiss estim price octob sort target price upside/downsid
pharma holt len
differ current price target priceholt defaultholt linkerequ pharmavalu pharmavalu pharmavalu npv charl martineau univers toronto octob
credit suiss offer three proprietari valuat tool sector holt
default holt len linker pharmavalu essenti dcf model
differ area focu model underli cash flow compani
pharmavalu provid product-by-product npv approach captur drug-specif trend
catalyst sensit holt framework aim captur return valu compani
use true balanc sheet balanc sheet often ignor element pharmaceut
analysi greater focu sale margin holt use provid disciplin
ad perspect assess compani
holt default framework sophist discount cash flow model driven
two year consensu sale ebitda growth forecast model use return
metric call cfroi cash flow return invest asset growth discount rate
cfroi intern rate return gross cash flow adjust net incom inflation-
adjust gross invest adjust book asset adjust account ensur
compar amend recurr cash produc true pictur return
compar across region sector import adjust pharma
compani holt capitalis onto balanc sheet compar
sector adjust significantli reduc level return pharma compani
holt default framework explicitli forecast five year cfroi cfroi
cfroi use valuat deriv roll combin
consensu sale ebitda growth forecast fade four year base
empir outcom firm similar start cfroi growth featur thereaft
year model fade cfroi cost-of-capit asset growth
cfroi fade base holt observ aggreg cfroi time
show tendenc earn real rate return close
compani particularli high histor growing/st cfroi classifi
holt ecap compani empir competit advantag period case
explicit cfroi forecast window extend five year year extend
period fade initi boost compani valuat criteria
requir high cfroi level five consecut year cfroi
trend flat improv limit volatil holt fade period
univers five year alexion novo nordisk
recordati regeneron roch qualifi ecap note orion lost ecap statu
return discount back company-specif discount rate holt discount rate
equival cost capit comput use capit asset price model
instead market-deriv real cost capit compos three part countri base
rate averag system risk compani economi liquid premium
credit-risk premium cfroi discount rate model fade toward
ultim result zero econom profit outli year market assumpt
elimin termin valuat issu common approach
holt default model three main limit opinion valu pharma
comprehens consensu ep forecast avail two year caus
difficulti pharma compani pivot event date gener
known least five year advanc exampl patent expiri
pharma holt len
sector highli cash gener holt model accumul cash
balanc sheet reduc return opinion pharma compani invest cash
 asset distribut share buyback dividend
use region discount rate base countri domicil believ pharma
global industri common among pharma compani among non-
pharma compani local market
holt linker aim address restrict use credit suiss estim drive
forecast cfroi level longer forecast window year restrict build-up
cash standardis discount rate across subsector
credit suiss pharmavalu proprietari valuat tool pharma biotech industri
offer product-by-product valuat compani base net present valu npv
life-cycl drug portfolio believ npv valuat approach
particularli valuabl pharma sector predict long-term cash flow
captur near-term earn potenti drug market long-term potenti
drug develop product within compani portfolio differ life-cycle
characterist peak sale potenti revenu ramp-up margin patent-expiri schedul
gener eros rate captur proprietari pharmavalu algorithm
use discount rate standard rate deriv npv termin
valu use analysi rel rather absolut valuat techniqu look
output two way ev/npv equiti npv per share report also run
pharmavalu databas compani discount rate combin holt
market-impli discount rate subsector inflat assumpt provid
compar discount rate holt
figur credit suiss holt pharmavalu valuat model
pharma holt len
use cfroi cash flow return invest elimin global account distort allow compar consist across industri countriesr profil expect cash flow driven consensu earningsestim next two year use forecast next forecast period determin histor cfroi profil volatil profil profil trend upward compani qualifi variabl label ecap forecast period extend default yr compani specific-fad algorithm built use histori guid systemat gaug cash flow profil look level volatil trend return growthus market impli discount rate modifi compani base domicil size leverag holt adjust balanc sheet capitalis oper leas adjust inflat holt assum excess cash accumul balanc sheet use cs global team drug forecast drug life-cycle algorithm calcul npv drug countri indic profit drug yet reach market assign probabl success sum drug valuat busi give pharmavalu npv design absolut valuat tool cover drug onward consist approach across product provid strong rel valuat tool good invest track record npv quot total equiti basi use discount rate balanc sheet independ howev analys product look aggreg invest npv pipelin time holt default frameworkus holt dcf model enter cs pharma research estim sales/margin cash flow provid insight expect level return growth profil due extern factor patent expiri new launch remain year forecast pharma team use profil sale pharmavalu databas complet forecast use averag default dr subsector therebi remov domicil depend b/ adjust manner holt default framework assum maximum sale compani histor averag sale retain holt charl martineau univers toronto octob
given clear global natur industri show context holt default
upside/downsid major stock global univers
base averag upsid stock list holt default suggest
greatest averag upsid major us biotech follow us major
eu major eu specialti holt default indic
downsid larger japanes pharma
figur show averag potenti upside/downsid stock base holt
default today bar project upsid downsid past year diamond past
month absolut share-pric perform octob stock rank within
sub-group current holt default upsid potenti
high potenti upsid biotech base extrapol recent
strong return biotech howev reach point matur
begin anticip patent expiri first wave product reach end
figur holt default up/downsid average up/downsid past month yr share price perform
credit suiss holt credit suiss research price octob
holt linker allow long-term explicit forecast
upsid holt linker rel holt default notabl almiral azn gsk
vifor
holt default valuat pose challeng pharma sector use robust
methodolog alongsid long-term forecast use holt linker holt linker enabl
us input credit suiss forecast make adjust holt default basic
framework includ cash flow build-up discount rate see appendix full detail
reflect certain characterist specif pharma compani believ import
holt linker valuat typic show upsid rel holt default reflect
long-term explicit forecast limit accumul cash allow linker
analysi pay excess cash would otherwis accumul balanc sheet
depress return lower oper asset assum drive profit busi
return rise linker justifi higher warrant price
pharma holt len
upsdi /downsid perf holt year averag holt yr share price perf oct charl martineau univers toronto octob
one key point compar holt default linker warrant price relat ecap
statu compani default algorithm ecap compani proven
cfroi record begin fade normalis long-term growth rate year rather
standard five year typic increas warrant valu compani current
rate ecap univers novo nordisk roch recordati
anoth factor discount rate holt linker use averag rate expect
univers compani rather rate holt default calcul
apocop rate base countri domicil size/leverag compani
work assum pharma compani similar
compani share size domicil
compani benefit see materi lower discount rate linker
default approach bayer almiral gsk grifol compani penalis
holt linker see higher discount rate novo nordisk roch novarti
compani holt linker suggest higher fair valu holt default
highlight almiral astrazeneca gsk vifor highest posit
discrep holt linker default common
acquisitions/invest see immedi return product ad exist
franchis almiral allergan dermatolog acquisit gsk pfizer over-the-counter jv vifor
continu strong ferinject growth azn growth come inflect point sale
profit headwind recent patent expiri annualis underli growth
theme
figur differ upside/downsid current price holt default holt linker rank linker upsid
almiral linker warrant price higher holt default price
believ larg reflect valu allergan dermatolog deal bolt
product onto exist platform immedi replac product lost patent
expiri return us oper profit assum commerci success
seysara reach peak sale linker also benefit use
discount rate rather holt default rate base almiral
spanish compani specif size leverag
azn linker upsid rel holt default reflect continu strong growth
explicit forecast recent wave patent expiri annualis
new specialti drug continu grow strongli assum higher tagrisso
sale compani consensu data
pharma holt len
differ current price holt linkerholt default current charl martineau univers toronto
compani holt linker suggest lower fair valu holt default
novo roch ucb see lower warrant price holt linker holt
default case see chang level futur competit expect put
pressur sale limit return may obviou extrapol futur return
recent return two year ep forecast
ucb linker reflect impact patent expiri vimpat
cimzia shift expect group sale growth declin
novo shift relianc insulin inject glp enter oral
antidiabet market impact see substanti cost compani move
oral drug tradit payer look lower price point
compani provid bigger discount payer formulari
posit invest sg broader rang doctor typic
prescrib inject novo also suffer higher sector-averag discount rate
linker markedli higher use holt
default driven compani domicil denmark size lack leverag
roch biosimilar cap growth profit estim next year
expect price pressur us emerg greater scrutini
price although roch increasingli confid weather like first
full year us biosimilar eros declin sales/profit investor appear
cautiou
view eu major broadli fair valu pharmavalu equiti npv
averag current share price full npv ahead current
share price eu specialti averag fair valu uplift full npv
use discount rate lift averag upsid equiti npv eu
major eu specialti
given lack coverag us major cs current time report focu
eu compani figur show npv/ev univers bar extend
beyond npv excess ev persist investor presum
agre forecast expect manag abl either reinvest cash flow
sustain return make adequ return sharehold
analysi includ disclos product development-stag project
compani platform technolog may expect gener intern project
bolt-on acquisit could extrem profit leverag exist underutilis
market platform compani may trade appar premium tangibl net present
valu look expens extend period time
eu compani look particularli inexpens metric includ almiral sanofi
almiral acquir allergan dermatolog drug sold
exist us dermatolog salesforc in-licens ilumetri complement
asset skilar also improv eu dermatolog franchis almiral
expand rel low price point product market becom
focu larger compani
sanofi compani larg tail old rel stabl product beyond patent
shock make look inexpens product high net present valu
requir npv effect share econom dupix partner
regeneron concern overst valu sanofi
longev
pharma holt len
book end-us sale look new manag focu certain
element busi reduc relianc wide rang oper
merck kgaa healthcare-bas conglomer sum part
includ conglomer discount investor may demand dispar
portfolio half valu come non-pharma oper remain
confid group strong posit life scienc tool perform materi
model/valu yet includ announc versum transact
due close end
eu compani look expens metric includ orion recordati vifor
recordati recordati busi model call around growth
organ around inorgan acquisit group strong eu
infrastructur prove abl absorb product acquisit
astrazeneca old cardiolog brand seloken good exampl
immedi accret addit sale recordati embark market
re-establish declin brand previou owner azn
pharmavalu methodolog valu deal yet conclud
new privat equiti owner control stake new chairman
fleme ornskov acquisit record investor appear expect
similar deal low multipl without advers affect recordati current
orion finland-bas specialti pharma compani local eu oper orion
remain import domest oper sale suffer result
recent finnish govern price restrict rest europ push
biosimilar result lumpi revenu continu help bridg next wave
product led nubeqa/darolotamid prostat cancer partner bayer
orion highli leverag success product made slow start
first market us although still earli day bayer put lack initi
script compar competitor erleada time point post launch
earlier-than-expect approv suppli delay remain sceptic
abil lower side-effect profil drive market share gain competitor
broader label stronger abil contract payer good formulari
vifor swiss-bas specialti compani focu anemia kidney diseas
joint ventur freseniu put strong posit in-licens
product develop market kidney specialty/dialysi centr investor appear
prepar pay premium current asset reflect opportun
figur length bar show rang ev/npv possibl base
full success failur dark grey central area look success failur drug
greater po white extens show impact success failur drug
po spot repres current ev/npv
success spot would move bottom bar everyth fail
ev would move top bar
compani highest sensit includ astrazeneca roch novo
nordisk bar larg repres eu oral semaglutid approv us
file eu probabl high limit upsid regulatori
pharma holt len
figur pharmavalu npv ev pharma univers
figur show pharmavalu npv standard discount rate show
total npv unadjust net debt/provis equiti npv also show equiti
npv discount rate long-term work alway use discount rate
view mirror minimum intern hurdl rate use make invest decis
industri us eu howev era low interest rate worth
flex discount rate check sensit rate bring approach line
holt approach base assum discount rate long-term rate
one might expect biggest differ discount rate appear
compani valu driven long-term franchis smaller
differ compani valu deriv near-term sale
figur pharmavalu equiti npv differ use discount rate
pharma holt len
kgaabayeripsengskrocheaznnovonordisknovartisvifororionpharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug current priceequ pharmavalu pharmavalu pharmavalu charl martineau univers toronto octob
holt adjust effect doubl aggreg ifrs/gaap balanc sheet
eu major add eu specialti cfroi includ goodwil
run eu major eu specialti like similar wacc
pharma specialist tend focu sale growth margin cash flow primari
driver model larg ignor element balanc sheet apart work
capit net debt part reason widespread differ report
balanc sheet similar compani use amount physic cash grow one
invest notabl differ report
balanc sheet holt attempt remov differ remov account distort
 make adjust asset base way holt look gener
estim total invest capit pharma industri biggest impact
substitut expens capitalis invest base
asset life year holt also inflat adjust gross plant capitalis leas
normalis compani leas facil
figur figur illustr rel size balanc sheet holt
vs ifr compani includ goodwil well gross cash flow diamond rh
holt eu pharma balanc sheet aggreg larger ifr balanc sheet
novo roch stand eu major adjust holt balanc sheet
higher ifr azn case larg driven high level
holt capitalis
capitalis leas inflat adjust age pp account
increment balanc sheet versu ifr roch novo lundbeck orion holt
gross cash flow typic higher ifr cash flow exclud cost
oper leas expens capitalis holt balanc sheet
figur comparison ifr holt balanc sheet eu major pharma
figur comparison ifr holt balanc sheet eu specialti pharma
pharma holt len
bs ifr vs holtgoodwillintangpp ewk cap/cash/othercap leases/infl adj/acc depncap dcash grl mclonn vxlun comrcg deornbv hereci miucb brvifn scomp bs ifr vs holtgoodwillintangpp ewk cap/cash/othercap leases/infl adj/acc depncap dcash charl martineau univers toronto octob
invest return overst lack captur
invest ifr balanc sheet
figur figur illustr variou measur return invest capit use
tradit ifr holt augment balanc sheet
ifr basi roce includ goodwil averag major pharma
specialti pharma lack captur signific invest onto balanc
sheet ifr act artifici inflat appar return holt allow us add
invest back see roce adjust balanc sheet fall averag
eu major eu specialti case still well ahead expect
cost capit
holt cfroi tradit quot return exclud goodwil basi goodwil
typic acquir deal investor wish see return pharma team
alway focu possibl return includ goodwil call transact cfroi
look cfroi metric holt averag cfroi major pharma holt
sector ignor goodwil includ goodwil specialti pharma
averag exclud impact goodwil includ goodwil
cfroi region would estim compani wacc
figur eu major invest return metric ifr holt balanc sheet
figur eu specialti invest return metric ifr holt balanc sheet
pharma holt len
cfroi novo stand best long-term perform
figur figur show progress transact cfroi time eu
major specialti pharma novo nordisk stand highest cfroi today
azn almiral stand would expect number see strongest
improv cfroi move older newer portfolio drug
compani new product abl sold establish infrastructur limit requir
cost growth
figur transact cfroi holt linker time eu major
figur transact cfroi holt linker time eu specialti
figur figur illustr sector aggreg cfroi within separ
cfroi take account valu acquir goodwil transact cfroi
ad increment cfroi calcul goodwil ignor also show market-
impli discount rate time arguabl good proxi holt cost capit
holt default model major pharma subsector earn cfroi
cost capit discount rate throughout past year goodwil eu compani
univers typic averag eu major eu specialti japan pharma
struggl keep cfroi holt cost capit sinc eu specialti pharma
also occas struggl shown notabl improv recent year
major pharma eu cfroi profil contrast us major declin sinc
forecast improv base consensu estim us major
compani aggreg alreadi seen improv trend cfroi
pharma holt len
pharma holt len
valuat
overal score well eu pharma roch recordati orion look attract
look beyond tradit cfroi-impli valuat work holt offer number
screen scorecard add momentum measur recent ep revis qualiti
measur cfroi level sustain valuat
holt see factor indic superior growth investor return highlight
pharma compani score measur momentum oper
qualiti potenti realis higher return analysi look
select pharma/biotech compani rel univers pharma compani
cut-off market cap compani look attract qualiti
momentum appear upper right quadrant figur
eu compani coverag appear everi quadrant roch recordati orion
show attract
roch impress record larg intern driven recent earn revis
reflect strong uptak new drug lower-than-expect profit impact biosimilar
recordati highli acquisit state goal drive around earn
acquisit around organ growth new ownership privat equiti
control stake enhanc board chairman flem ornskov formerli shire
deal make appear increas
orion consensu earn revis highlight holt believ may reflect
analyst start reflect inclus mileston recent us approv
commercialis daruolutamid prostat cancer partner bayer
compani histori deal score poorli approach includ takeda
investor remain disappoint time synergi shire acquisit
figur momentum oper score compani rel global sector
pharma holt len
llypfebmyjnjabbvmrkgskaznsasybaygnnovobrognovnalmipnornbvrecivifnucblunmrcglonnamgnbiibgildregnvrtxcelgtakedadaiichi rank measur recent ep revis flow cfroi qualiti rank measur level sustain recent charl martineau univers toronto octob
roch novo nordisk attract eu major holt scorecard
holt scorecard build oper qualiti momentum criteria overlay
valuat oper qualiti momentum valuat weight
compon outlin figur
figur holt scorecard factor includ weight exampl gsk
figur overal score select pharma/biotech score august august
depend score metric compani alloc invest style
outlin figur current invest style lead pharma biotech
compani shown figur holt classif invest style updat
month chang aggreg score time key pharma compani shown
figur figur typic compani overal score assign best
class lower worst class score rel compani
domicil rather within global sector us pharma score rel well
us compani major score much higher dispers score
pharma holt len
among eu major roch novo score strongli although roch qualifi
best class azn score worst overal translat style momentum trap
figur invest style global basi
pharma holt len
invest themeoper qualitymomentumvaluationbest classgoodstrongcheaprestructuringpoorstrongcheapcontrariangoodweakcheapqu pricegoodstrongexpensivevaluetrappoorweakcheapmomentum trappoorstrongexpensivequ trapgoodweakexpensiveworst score best classrestructuringqu trapmomentum trapneutralcontrarianqu pricevalu trapworst charl martineau univers toronto octob
figur us major chang invest style score time
figur eu major chang invest style score time
figur eu specialti chang invest style score time
pharma holt len
perform holt invest style
perform holt invest style assess differ econom cycl
give indic style work best particular macroeconom condit holt
develop holt cycl clock deriv global industri product metric
calcul maintain econom strategi group invest solut
product team within intern wealth manag divis credit suiss
holt cycl clock indic global econom cycl still contract
support invest case ecap best class best perform
invest style contract across variou econom cycl best class
remain consist one best perform style similarli worst class
consist rank worst perform style
holt compani data credit suiss estim note holt qualiti holt momentum
pharma holt len
sector
holt account qualiti model assign weak bottom quintil score major
pharma azn sanofi bayer specialti almiral lonza merck kgaa
well-known exampl azn externalis incom includ incom
high level deal-rel amortis also routin exclud company-report
ep sens eu pharma compani show highest
level ep adjust market look eu sector aggreg data holt
time allow us put percept test figur show differ
report ep non-gaap ep past five year rang sector
base european compani aggreg market cap show
percentag uplift non-gaap ep report ep median basi skew
result toward smaller compani sector also market cap weight averag
basi pharma number distort rest healthcar much
distort consum discretionari consum stapl
figur non- ep
holt look qualiti compani disclosur rank compani across number
area score region sector-specif believ overal low score could
start point identifi potenti risk might warrant investig
figur highlight holt rank account qualiti compani holt
weight base equal weight import quot holt total account score
weight factor follow
revenu recognit overal score categori look specif trend within
account receiv defer revenu percentag account receiv
expens recognit overal score categori screen chang
import item depreci account payabl inventori may indic
attempt defer minimis hide cost busi
balanc sheet overal score categori identifi qualiti
balanc sheet liabil asset includ oper leas pension liabil
flow overal score relationship earn cash flow
import econom signal account qualiti model use holt proprietari
calcul econom cash flow comparison accounting-bas earn
pharma holt len
disc industrialsconsum stap materialsutilitiesinfo techcommun serv market market market market market market market market market non ep yr ep average non market cap yr average non charl martineau univers toronto octob
figur aggreg score compani four key metric base
region rank quintil equal weight compon lowest possibl
score four highest basi us major pharma score broadli line
us sector eu pharma score typic averag eu us biotech score
averag chugai stand qualiti account japan eu us major
typic score bottom quintil cash flow top quintil balanc sheet
recognit eu specialti compani typic score well metric
worth compar figur highlight holt qualiti figur
highlight differ compani report ep adjust ad
cs analyst improv compar
worth note holt accumul intang asset balanc sheet
factor weigh neg account score howev fact life
acquisit pharma compani add pharma compani look weak relat
sector
compani stand rel poor account qualiti score holt azn
sanofi bayer major pharma almiral lonza merck kgaa specialti
bayer score overal bottom quintil europ holt rate poor revenu
recognit balanc sheet account averag expens recognit cash
flow bayer recent decreas disclosur level group longer provid
granular division level show either gross net cash flow
sanofi also score bottom quintil overal poor cash flow balanc sheet score
averag revenu expens recognit outsid holt would
highlight poor account sanofi sector-averag cash convers limit use
except restructur charg howev would welcom frequent cash flow
disclosur simplifi reconcili non- number
merck kgaa score averag overal holt highlight poor revenu recognit
below-averag cash flow balanc sheet account see cash flow gener
match cs ep
figur holt account qualiti score four metric aggreg
intang amort expens expens holt team highlight
healthcar sector one affect intang amortis asset
median impact report ep impact price-to-earnings
pharma holt len
score max factor max overal qualiti revenu recognitionaccount qualiti expens recognitionaccount qualiti balanc sheet recognitionqu earn charl martineau univers toronto octob
figur intang amortis boost non-gaap ep sector
holt len factset data univers largest compani market capit ex
financi estat util note intang amort boost non-gaap ep holt
estim calcul divid estim after-tax amort impact ep spread gaap
non-gaap ep
figur show detail account qualiti highlight holt typic see
gross cash flow special item past four year across subsector pharma
figur holt account ep cash flow
pharma holt len
squibb eli hold nordisk pharma lundbeck group scienc pharma co sankyo compani co vs non-gaap ep spreadspeci item gross flowaccount qualiti special item charl martineau univers toronto octob
eu analyst perspect account
outsid holt account qualiti factor look close attempt normalis
account across sector enabl better cross-compani price-to-earnings comparison make
routin ignor deal-rel amortis except recordati acquisit
major part busi model intern cash invest low
exclud forecast profit sale drug major
azn externalis incom feed back incom time
one-off larg payment capitalis exampl exclud on-going
incom almiral reflect effect late book one-tim
sale respiratori asset azn second exampl merck kgaa
exclud one-tim payment pegpal includ
bavencio mileston incom remain core product
exclud major restructur charg note univers compani
charg except restructur charg sinc typic
charg run around sale
specif charg effect royalti expens lie outsid ep
azn payment diabet portfolio gsk effect
royalti payment shionogi sale
pharmavalu analysi modifi assum margin project
overal impli level profit fit close possibl cs adjust net incom
ensur treat compani irrespect choos report
profit us biotech compani typic exclud stock option ep
includ cost calcul profit pharmavalu work keep
basi compani univers explain differ
credit suiss ep compani gilead figur biotech team
exclud stock option publish credit suiss ep global
pharmavalu analysi improv compar
figur varianc ep report ep cs ep free cash flow per share
juli azn paid almiral up-front includ develop mileston launch
sale relat mileston plu unspecifi royalti respiratori portfolio centr aclidinium product
estim write-back incom total ebit
pharma holt len
avgabbvagnbmyjnjllymrkpfetevaamgnbiibcelggildindex ep epsfcf per share ep charl martineau univers toronto octob
chart show bridg incom past six-and-a-half year look
aggreg differ report underli earn figur
look compani subsequ figur show subsector detail
within eu univers notabl differ compani ep
credit suiss ep mani case free cash flow per share close track credit
suiss ep ep vindic adjust continu make
figur eu non- cs ep index non-
figur us major non- cs ep index
figur us index non-gaap net incom
figur aggreg global data index non-gaap net
pharma holt len
pharma score well rel sector biotech compani relianc
high-pric specialti score best
holt look resourc effici across number criteria feel address element
pertin esg invest look rel perform univers pharma
compani perform pharma key sector
four resourc metric look pay perform also import
contributor govern aspect esg
analysi look number employe amount water emiss
wast produc associ gener one dollar holt econom profit holt
team look trend past five year compani
world indic highlight compani effici metric improv
figur highlight rel posit compani within pharma univers
case look median valu metric past five year rel
industri averag score level improv median
holt gross cash flow/employe number measur oper
effici pharma differ score may reflect differ busi model
particular compani strong em exposur like significantli higher
salesforc compani may score better access medicin
holt gross cash flow/per cubic metr water use reflect
manufactur intens although arguabl lower use water prefer note
novo introduc oral semaglutid rebylu sold alongsid inject
version drug ozemp would expect water consumpt per weekli
dose drug increas oral version drug conveni
mani patient current requir around activ ingredi level inject
version broadli similar efficaci introduc conveni product novo
arguabl make small environment sacrific patient prefer like
holt gross cash flow/per tonn emiss metric favour
compani high-pric specialti inject product tradit lower-pr
tablet drug compar compani also import look use contract
manufactur increasingli common highli complex biolog check
emiss includ compani report holt found strong correl
emiss energi consumpt
holt gross cash flow/per tonn wast produc unsurprisingli
metric pharma sector shown strongest improv
data show appar low intens resourc biotech versu pharma believ
reflect high price specialti product biotech particular typic sell
small number high-pric specialti drug although compani look strong
metric may score well access medicin afford
figur look improv five year score metric
give compani score deterior improv
score improv least median level sector across
metric score metric median improv
minimum possibl score therefor maximum possibl score
note azn novarti appear shown rel low start score
recent improv metric
pharma holt len
figur compani data rel pharma sector median resourc invest
figur compani data rel pharma sector improv resourc effici past year
figur pharma healthcar resourc intens versu key sector
figur compani data rel pharma sector improv resourc effici past year
pharma holt len
data vs sector average max set gcf employeegcf emissionsgcf /wast improv past yearsgcf employe improv scoregcf withdrawn improv emiss improv scoregcf /wast produc improv cgoodsbas materialsconsumerdiscr consumerstaplesutlitiesretailpharmahc servicesm techcomani data vs sector average max set gcf employeegcf withdrawngcf emissionsgcf /wast cgoodsbas materialsconsumerdiscr consumerstaplesutlitiesretailpharmahc servicesm techindex improv past yrsgcf employe improv scoregcf emissionsgcf /wast charl martineau univers toronto octob
pay perform
roch novo nordisk show highest econom valu creat per ceo
pay past three year
key metric holt econom profit calcul differ
cfroi discount rate effect valu ad multipli gross invest
base given import acquisit sector rel high level goodwil
invest base continu use transact cfroi metric figur
look three-year averag ceo pay averag three year econom
profit although one could queri appropri lag result pay
analysi believ provid use start point work
ceo pay econom profit shown rel scale within cover
compani worth note ceo pay stand base larg histor pay
ceo compens mani us compani tight band
ceo receiv us biotech compani
list rang led regeneron gilead highest ceo pay
 european major ceo pay rang azn roch
top end pay scale
compani appear gener highest econom return relat ceo pay
unsurprisingli eu base given typic lower ceo pay roch novo nordisk
top analysi
figur ceo pay rel econom profit gener
pharma holt len
rel econom profit average rel average pay ceo charl martineau univers toronto octob
 lifeblood industri
research develop lifeblood pharma industri drug see
effect patent life around year compani need continu invest replenish
portfolio done intern via pipeline-focus acquisit past
five year eu univers compani invest around expens
 capitalis around addit spent
acquisit much effect addit improv product
seen increas number approv recent year investor clearli want look
 effici holt pharmavalu offer tool compar data
figur develop peak sale potenti newli approv drug
roch recordati orion score best rel peer holt measur
holt capitalis report deriv adjust balanc sheet compar sale
year allow simplist analysi effici note like
underestim invest overestim return compani new product
acquir effect capitalis associ intang asset
spend although drive sale captur intens analysi
figur compar measur effici amount spent
percentag gross invest ideal compani invest significantli gener
posit return optim posit top right graph
stand greater invest proport overal gross
invest base typic lead superior return
pharma holt len
 new launch spot us peak sale yr us lch bar sale nda sale s-nda sale bla sale s-bla sale bla-b sale etcpeak sale us overallu charl martineau univers toronto octob
us biotech unsurprisingli tend show high level gross invest
togeth us major japanes pharma compani tend show low level
 takeda stand low level ignor effect
 captur acquisit shire almiral also show limit arguabl
larg part acquisit allergan dermatolog portfolio larg acquir
seysara almiral develop intern intens would much higher
although yet asset would show sale would move almiral
toward top left quadrant
recordati lonza stand highest sale per dollar holt
reflect differ busi model lonza limit requir
rel form invest pp intens recordati also
low level cash invest quot percentag sale
major cover amortis past capitalis acquisit
spend cash recordati run around sale
figur sale capitalis vs gross invest
 return pharmavalu
latest data suggest broadli stabl product follow declin seen
sinc azn screen well term replac power orion ipsen
term return current cohort new launch
credit suiss databas track drug includ everi
drug forecast complet life-cycle see figur allow us calcul crude npv
per drug compar npv cohort drug spend appropri
lag estim chang effici time
analysi take expens though add either in-
process us capitalis ifr ensur captur
complet level invest possibl figur show appar recent
declin product overal although see record number product
approv regul mani orphan drug limit indic revers
recent trend improv attribut move toward biolog long
life-cycle high npv given level sale sinc seen increas
pharma holt len
llypfebmyjnjabbvmrkgskaznsasybaygnnovobrognovnalmipnornbvrecivifnucblunmrcglonnamgnbiibgildregnvrtxcelgtakedad intesnt holt gross invest dr return sale /holt yr capitalis charl martineau univers toronto octob
proport tradit small-molecul drug tend lower npv
project life-cycle biolog also see uplift level requir drive
pipelin reflect increas process effect capitalis pipeline-
centric acquisit includ analysi
figur npv product npv year lag spend
figur show recent product variou eu compani look peak sale
potenti drugs/r spend three time point figur look npv
 d/npv spend meaning measur real return view investor
key measur abil pipelin refresh current portfolio figur
look npv pipelin divid npv current portfolio topic
revisit annual regular pharmavalu report includ detail explan
methodolog idea engin global pharmaceut pharmavalu strateg
analysi also allow assess level uniqu portfolio time
crucial view sustain price power chang overal level uniqu
expect next year highlight figur
figur product histor current futur peak pharma sales/relev spend
pharma holt len
 yr spendu larg capeu larg kgaaorionrecordatiucbpeak sale /lag periodsr productivityadd charl martineau univers toronto octob
figur compani product npv d/npv spend recent futur
figur replac power npv recent launch new product establish portfolio
figur level uniqu time oper margin
pharma holt len
power npv d/npv spendrec product npv lch spend product npv lch npv power ratio npv d/npv establish drugsnpv recent ches/establish drugsnpv nt pipe /establish drugsnpv lt pipe/establish margin line ww econom brand drug sale uniquesustain branddiscountablesubstitution/gener riskmultihc op charl martineau univers toronto octob
see expect free cash flow next five year unaccount
term current project dividend share repurchas announc
analysi capit deploy import driver return within
pharmavalu work see compani high npv relat ev refus re-rat
investor concern impli high cash flow inappropri reinvest
therefor ultim return investor focu cash
use histor forecast use futur holt also provid data
histor cash deploy across broad rang compani
take opportun illustr use free cash flow pharma sector
demonstr discretionari expenditur cash flow adjust standard definit
cash flow ad back alongsid invest disburs
end calcul eu pharma gener around
adjust free cash flow aggreg compani invest around
 acquisit return sharehold via dividend
via share buyback overal account adjust free cash flow
sector take around increment net debt period
next five year forecast strong growth free cash flow
sector around assum reinvest
alreadi earmark follow-on payment alreadi announc acquisit assum
free cash flow return via dividend via share repurchas leav
free cash flow unaccount current assum use pay
debt could use boost ep via share repurchas fund acquisit
figur eu pharma sector use adjust free cash flow
figur exampl cash deploy holt novo
pharma holt len
debtdividendr adj tax net share repurchaseacquisitionscapitalised/inprocess dfree adj charl martineau univers toronto octob
figur actual use cash flow jan
figur forecast use cash flow jan dec
holt cash deploy
holt offer long-term histor view use cash share issu
compani page compani report/options/cash deploy figur show
breakdown use cash flow major compani figur
novonordisk use cash recent year note holt analysi agnost
level cash gener highlight increas leverag pay
debt highlight analyst model
figur use cash flow
pharma holt len
use adj tax cap dnet share use adj tax cap dnet share cash expens gross capit expendituresd equiti acquiredr expensenet share buy-back common prefer charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
top pick us almiral kept us infrastructur lost us dermatolog sale abl
profit immedi allergan dermatolog acquisit success initi launch
seysara acn support view dermatologist respond well new
innov next leg growth come europ roll-out skilar
ilumetri psoriasi asset tiranibulin actin keratosi lebrikizumab
atop dermat almiral may offer innov skilar oral product
abil offer lower price major competitor
pharma holt len
tapeduaklirebastelpoli derma skilarenceilumetriseysaranpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
almiral one biggest discrep ifr holt balanc sheet
holt balanc sheet doubl size ifr bs figur
almiral forecast holt linker strongest improv ultim one
highest cfroi sector medium term figur
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe sa alm ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
continu see astrazeneca top pick owe top-lin growth underli
margin recoveri potenti impress pipelin show strong replac power rel
peer see figur new therapi approv provid top-lin growth expect
growth bottom line increas margin owe mix shift toward uniqu
product figur particularli evid oncolog forecast top-lin growth
requir signific increment sg invest alreadi establish
pharma holt len
per share gbp total brand drug npv per share gbp stageaddit npv probtot brand drug npv per share total group npv per share gbp labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
expect azn show highest improv cfroi group show acceler top-lin growth limit cost growth allow
margin improv
pharma holt len
current price usd price usd date growth parallel point chang forecast dec growth mgn turn rate grth book pe plc azn ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
bayer pharma
figur potenti contribut new drug
figur uniqu portfolio time
credit suiss restrict bayer role announc anim
health transact commentari restrict pharma agrochem
pharma busi face challeng onward eylea competit ramp
xarelto patent expir see activ near medium term necessari
fill void howev note recent investor discuss center possibl patent
extens xarelto consider confid futur perform
agrochem busi market-lead germplasm seed good
replenish prospect across area agrochem segment also uniqu
posit take advantag rise digit farm platform fieldview
pharma holt len
gene therapi baybay women healthyasminadempasglucobaykogenate/helixate/jivibay aspirinmirena familyeyleaxareltonpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
credit suiss restrict bayer show holt analysi base consensu
estim avail holt len show valuat data base credit
suiss forecast may inconsist forecast use consensu number
analyst like move anim health discontinu oper
follow propos dispos announc
pharma holt len
figur potenti contribut new drug
figur uniqu portfolio time
gsk transit manag concentr rebuild pipelin drive growth
pharma integr over-the-counter unit ahead expect separ ipo
divis next year biggest singl driver npv group new shingl
vaccin shingrix current roll-out phase sale limit capac constraint
group vaccin oper world class high barrier entri expect respiratori
portfolio remain broadli stabl advair us eros occur slow
expect transit newer drug nucala trelegi expect hiv franchis
remain essenti flat enhanc competit gilead off-set launch dual
drug regim strong data need overcom entrench mindset tripl therapi
best gsk remain highli sensit fx move larg dollar earn sterl cost
pharma holt len
matur bet inh tb vaccin ico agonist otilimabtsr attach inhibitordaprodustatcabotegravir tgfb trapmekinist/tafinlarinfanrixbenlystativicayengerixb/havrixtrelegi elliptabreo elliptagsk mening vaccinestriumeqnucalaadvairshingrixnpv per share gbp total brand drug npv per share gbp stageaddit npv probtot brand drug npv per share total group npv per share gbp labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
holt linker see profit growth accru over-the-counter jv integr also
profit tesaro acquisit like seen beyond two-year consensu time
horizon use holt default worth note howev holt linker measur
cfroi pre goodwil goodwil account balanc sheet
pharma holt len
current price gbp price gbp date growth parallel point chang forecast dec growth mgn turn rate grth book pe plc gsk ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
grifol strong posit alongsid takeda global plasma market
barrier entri high market record growth pa heavi
invest need plasma collect centr fraction capac ensur enough raw
materi suppli satisfi demand grifol recent step number collect
centr short-term depress effect margin soon complet tie-up
shanghai raa see group sell major diagnost unit exchang
effect associ stake chines quot compani invest rel low
compar specialti pharma remain concern time taken
capitalis strong initi clinic trial result plasma ig ambar project
alzheim yet announc next phase trial design time see
limit opportun disrupt busi reflect continu rel high
pharma holt len
grifol ig grifol npv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin sa grl ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
recent revisit somatulin forecast cut reflect expect greater
gener competit class first novarti compet drug sandostatin lar europ
seen today like time somatulin despit complex manufactur
dysport ipsen brand botulinum toxin remain strong cash gener need
wait us paloveroten approv provid next posit catalyst growth
forecast ipsen substanti unalloc cash flow next year
remain nervous may reinvest
pharma holt len
maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin sa ipn ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
lonza pharmavalu perspect address
figur index opportun
pharma holt len
brand pharma market sale msmall moleculesimpl biologiccomplex biologicbiosimilarupto moleculesimpl biologiccomplex biologicbiosimilarful probabilityindex opportun biolgic sale mupto prob upto biolgic sale mupto prob upto molecul sale mupto prob upto sale mupto prob upto charl martineau univers toronto octob
contract manufactur key metric lonza cfroi figur illustr
believ growth biolog far outweigh growth tradit small molecul
biolog lonza focus lonza agnost commerci success
one particular product manufactur earn incom one-third recent
brand biolog expect specialti ingredi unit divest line state
strategi mind possibl dilut dispos ep immedi
reinvest pharma vertic integr potenti expans fill finish
pharma holt len
current price chf price chf date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin group ag lonn ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
lundbeck focus drug trintellix partner takeda rexulti
abilifi maintena partner otsuka number upcom patent expiri group
look product add infrastructur recent announc
acquisit alder late stage migrain drug ald eptinezuamb go way
fill gap prescrib doctor base differ migrain group
tradit area depression/schizophrenia see signific dilut group
add sale capac us eu eptinezumab fourth entrant
newli fill emerg cgrp class avail infus less competit
think alreadi launch sub cut product expect oral version believ
lundbeck find expens maxim commerci potenti product
peak sale forecast group earn adequ return
pharma holt len
ae franchisenortheralexaproabilifi maintenarexultitrintellixnpv per share dkk total brand drug npv per share dkk stageaddit npv probtot brand drug npv per share dkr total group npv per share dkk labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
lundbeck one biggest discrep ifr holt balanc sheet
holt balanc sheet three time size ifr bs figur
also one compani highest discrep holt linker
pharmavalu valuat holt look gener immedi return line histori
acquisit ad valu alder deal model see coupl year
heavi invest uncertain launch
pharma holt len
current price dkk price dkk date growth parallel point chang forecast dec growth mgn turn rate grth book pe lundbeck a/ lun ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth copi templat charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
merck kgaa healthcar conglomer lead posit number area
liquid crystal life scienc tool metal automot paint electron chemic
pharma divis strong multipl sclerosi franchis group use
experi rebif franchis inform launch novel mavenclad oral drug
merck shown strong immun oncolog research unit partner
bavencio recent bispecif pd-i/tgfb gsk shorter-term
interest group asset tepotinib c-met inhibitor forecast
po peak sale current unpartn family-control compani expect
group continu invest three divis ensur balanc oper
announc acquisit versum april close end year
deal yet includ forecast
pharma holt len
dna damag tgfb traphumira biosimilar mrcg serostimsaizenbavencioeuthyroxmavencladerbituxconcorgon frebifoth infertil merckglucophage/xrnpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin kgaa mrcg ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
novarti focus pharma oper shed invest vaccin consum
gsk spin alcon recent sell part us gener unit aurobindo
sale growth driven cosentyx indic breadth help sustain growth
although competit intensifi key driver growth entresto oncolog
franchis focu acquir new technolog larg success far
move radioligand pharmaceut via aaa endocyt see fast sale adopt
gene therapi avexi although invest car-t prove challeng
pharma holt len
per share chf total brand drug npv per share chf stageaddit npv probtot brand drug npv per share sfr total group npv per share chf labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price usd price usd date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin ag ex alcon pro-forma novn ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
top pick us see opportun novonordisk expand current footprint
diabet launch rebylu oral semaglutid howev price point oral drug
lower inject group off-set like trade oral
inject ozemp see overal size oral opportun compel clinic
data like drive strong oral adopt secur group growth mani year
continu focu diabet see strong sale growth minim margin
pharma holt len
anti per share dkk total brand drug npv per share dkk stageaddit npv probtot brand drug npv per share dkr total group npv per share dkk labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
novonordisk ecap compani algorithm fade kick year
rather five year ecap compani univers roch recordati
novo among biggest discrep ifr holt balanc sheet
holt balanc sheet around four time size figur
novo stand highest current forecast cfroi sector figur also
score well holt pay-for-perform analysi alongsid roch figur
pharma holt len
current price dkk price dkk date growth parallel point chang forecast dec growth mgn turn rate grth pe nordisk novob ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
orion finnish specialti pharma compani local eu oper orion remain
import domest oper sale finland although suffer recent
govern price restrict rest europ push biosimilar result lumpi
revenu provid bridg next wave product led nubeqa darolotamid
prostat cancer partner bayer orion highli leverag success
product slow start first market us still earli day
bayer put lack initi script compar competitor erleada time point
post launch earlier-than-expect approv suppli delay remain sceptic
materi lower side-effect profil drive market share gain
competitor broader label strong abil contract payer strong
pharma holt len
 biosimilarremicad biosimilardivinaburanaherceptin biosimilarcomtansimdaxstalevodexdoreasyhal franchisenubeqanpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
orion among biggest discrep ifr holt balanc sheet
holt balanc sheet around three time size figur
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe oyj ornbv ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
recordati busi model call around growth organ around
inorgan acquisit group strong eu infrastructur prove
abl absorb product acquisit astrazeneca old cardiolog brand
seloken good exampl immedi accret addit sale
recordati embark market re-establish declin brand
previou owner azn pharmavalu methodolog valu deal
yet conclud new privat equiti owner control stake
new chairman fleme ornskov acquisit record investor appear
expect similar deal low multipl without advers affect recordati current
pharma holt len
xlzanidipnpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
recordati classifi holt ecap compani histor cfroi record suggest
algorithm fade kick year typic five year
ecap compani univers novonordisk roch
recordati holt linker highest current cfroi see sustain
medium term figur
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe spa reci ebitda margin parallel point chang downsidewithin growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
expect biosimilar cap roch growth profit next year
expect price pressur us emerg greater scrutini us hospital-
base price call part reform and/or intern refer price although roch
increasingli confid weather like first full year us biosimilar eros
declin sales/profit investor cautiou
pharma holt len
per share chf total brand drug npv per share chf stageaddit npv probtot brand drug npv per share sfr total group npv per share chf labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
roch classifi holt ecap compani histor cfroi record suggest
algorithm fade kick year typic five year
compani univers classifi ecap novo recordati
roch among biggest discrep ifr holt balanc sheet
holt balanc sheet around three time size figur
roch score well holt pay perform analysi alongsid novo figur
pharma holt len
current price chf price chf date growth parallel point chang forecast dec growth mgn turn rate grth pe downsidewithin hold aktiengesellschaft ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroicfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthragrnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
sanofi look inexpens npv metric larg tail product old
beyond patent shock rel stabl high net present
valu reflect longev like high profit given limit market requir
npv effect share econom dupix partner regeneron
concern overst valu sanofi book end-us sale
look new manag focu certain element busi reduc relianc
wide rang oper
pharma holt len
gaaolipudas combolantusdupixentnpv per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin sasi ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto
figur potenti contribut new drug
figur uniqu portfolio time
holt linker show lower upsid holt default latter captur
eros profit like come patent eros cimzia
vimpat togeth make sale although ucb
follow-on biolog cimzia bimekizumab target subset current cimzia user
commerci potenti depend level price eros see categori
ultim clinic differenti ucb one compani univers
taken advantag low interest rate buy product increas leverag past five year
especi interest given view without extern deal sale like
declin wait see new cfo take differ stanc retir cfo figur
highlight expect forecast adjust cash flow gener spent
 holt default valuat see impact cimzia patent expiri
holt linker still give group benefit doubt term limit
impact margin expect declin sale
pharma holt len
royalti per share eur total brand drug npv per share eur stageaddit npv probtot brand drug npv per share total group npv per share eur labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
pharma holt len
current price eur price eur date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin sa ucb ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
figur potenti contribut new drug
figur uniqu portfolio time
vifor specialti pharma compani base switzerland strong focu anemia
kidney diseas establish infrastructur particular jv freseniu
lead dialysi supplier vifor strong posit in-licens drug promot
kidney diseas market forecast strong growth new product high contribut
pharma holt len
per share chf total brand drug npv per share chf stageaddit npv probtot brand drug npv per share sfr total group npv per share chf labsabbott labsabbott maddit new sale probprob adjust new drug salesexist drug lch post drug lch drug lch pre msustain branduniquediscountablesub riskgener charl martineau univers toronto octob
vifor forecast holt linker among highest cfroi level sector
pharma holt len
current price chf price chf date growth parallel point chang forecast dec growth mgn turn rate grth book pe downsidewithin pharma ag vifn ebitda margin parallel point chang growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto octob
cfroi return invest holt
measur return capit
cfroi emphasis compani cash gener abil take account inform
convert cash flow gener firm activ best way measur
underli econom indic whether compani creat wealth destroy
typic compani undertak specif project acquisit expans
new busi line prepar econom profil factor forecast amount
time cash outflow inflow estim project life intern rate
return calcul simpli compar firm hurdl rate decid
whether proceed project
figur calcul cfroi gross cash flow
holt expand premis appli mere specif project entir
compani cfroi translat ratio invest cash flow intern rate
return recognis finit econom life asset depreci build
residu valu asset necessarili depreci land cash like
irr calcul project cfroi metric proxi compani econom return
provid consist holist approach use compar perform across
portfolio market global univers compani transact cfroi return
advantag linker holt default
reiter opinion holt default model three main limit
comprehens consensu ep forecast avail two year restrict
abil captur known catalyst
use region discount rate given global natur pharma compani
similar non-pharma compani domest market
sector highli cash gener holt model accumul cash
holt linker aim address restrict use credit suiss analyst estim
drive forecast cfroi level longer forecast window year restrict
build-up cash balanc sheet standardis subsector discount rate
pharma holt len
figur princip adjust ifr holt balanc sheet
credit suiss explicit forecast holt linker
use forecast compani line
balanc sheet mean holt linker captur event key
concern/interest investor pharma sector includ patent expiri new product
launch well incorpor view chang margin larg effect
valuat
second half forecast period drive two
basic assumpt sale margin
sale assumpt assum sale fade grow
pharmavalu databas univers compani compound-annual-growth-rate sale growth
brand drug sale includ probabl adjust pipelin product
probabl success rise base assumpt therefor account
growth busi addit earli stage pipelin product current
captur pharmavalu expect acquisit add sale
margin assumpt take averag forecast margin
end explicit forecast period return normalis long-run rate
cfroi growth rate use standard holt fade arithmet one
driver differ holt default holt linker delay
start fade five year use compani exclud design
ecap year
second adjust make pharma holt linker differ holt default
discount rate holt default calcul forward-look country-specif discount rate
determin market adjust base discount rate size express
liquid leverag compani calcul company-specif rate holt
linker adjust discount assum pharma compani common
non-pharma compani domicil countri therefor
overrid company-specif discount rate appli fix valu subsector
pharma holt len
holt capitalis base year expens capitalis biggest adjust ifr b/ major pharmacompani capitalis add overal base invest special take gross level invest appli inflat adjust rel small element real invest capit pharmav sectorsholt primari cfroi calcul exclud valu goodwil invest base howev investor look return overal invest valu subject continu debat holt capitalis leas normalis compani facil leas pharmasector littl impact overal level invest capitalcapitalis charl martineau univers toronto
simpl averag holt market-impli discount rate compani sector
use discount rate detail specific-compani holt default discount rate
shown figur
figur discount rate use holt default holt linker
refinitiv compani data holt len credit suiss estim price octob
third adjust make pharma holt linker meaning impact
differ treatment surplu cash flow gener time model level gross
invest base explicitli incorpor directli forecast much cash
distribut back investor buyback dividend vs much retain part
oper capit base use base assumpt restrict amount
cash retain balanc sheet holt linker maximum sale
assum cash invest distribut rather accumul balanc sheet
adjust reduc penalis pharma sector return holt owe
awar adjust import use holt len holt len allow
investor load analyst forecast flex overlay specif investor opinion
howev cash adjust one flex option flex remov
credit suiss analyst background cash assumpt thu may chang flex
valuat expect understand scale analyst adjust
impact holt cfroi therefor import
pharma holt len
targetccypricewarr price monthsdiscount rate warrant price monthsdiscount rate equiti npv variou discount ratesdiscount rate inflat mktd drug /shrr d/shrcalc total seg npv pstotal npv ps equiti npv per rate real- market deriv pharmavaluesholt linkerholt charl martineau univers toronto octob
believ npv-base valuat methodolog particularli relev
pharmaceut industri abil captur near-term earn potenti drug
market plu long-term revenu profit potenti drug develop
product within compani portfolio differ life-cycl characterist peak sale
potenti revenu ramp-up patent expiri schedul gener eros rate peak margin
captur proprietari pharmavalu algorithm
use nine key data input proprietari algorithm build revenu profit life-cycl
drug calcul npv earn contribut product-by-product basi
sum individu drug valuat combin valu non-pharma busi
gener consum health yield total npv compani within
coverag univers enabl identif key long-term valu driver provid
product-by-product valuat full detail nine key input drive npv set
figur advantag product-by-product valuat abil determin
rel import success/failur also rel import earli patent loss
shape eros curv end life-cycl
databas current cover drug around market
develop
acknowledg pipelin valuat depend extent compani disclosur
